As multiple RIPK1 inhibitors (Nec-1s, GSK′481/GSK′772, etc.)have been advanced beyond Phase I safety studies in human clinical trials (67, 68), the authors suggested that the RIPK1 kinase inhibitors may provide effective therapy for severe COVID-19. This evidence concerns the gene RIPK1 and COVID-19.